The FDA granted approval to a novel class of medication on Friday for women experiencing painful hot flashes brought on by menopause.
The once-daily Astellas Pharma medication is approved by the Food and Drug Administration to treat moderate-to-severe symptoms, such as sweating, flushing, and chills. Veozah, a medication from Astellas, takes a novel strategy by going after the brain connections that regulate body temperature.
The drug will offer “an additional safe and effective treatment option for women,” according to a statement from the FDA.
The FDA stated that when the body gradually generates reduced quantities of reproductive hormones between the ages of 45 and 55, more than 80% of women experience hot flashes during menopause.
Hormonal supplements that increase levels of estrogen and progestin are the most widely used form of treatment.
However, some women—including those who have a history of stroke, blood clots, heart attack, and other medical conditions—do not respond well to the medication.
Despite the fact that the dangers vary depending on a variety of unique characteristics, large studies have indicated that hormones can raise the likelihood of those issues repeating.
There is no hormone in the new drug. The FDA has issued a warning regarding possible liver harm.
According to the FDA label, women will need to be checked for liver disease or infection before receiving a prescription, and they will then need to obtain blood tests every three months for nine months to check for safety issues.
JOIN US ON WHAT'SAPP, TO GET INSTANT STATUS UPDATES AND BE IN THE KNOW.
CLICK HERE
